SIGILON THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 23, 2020, by and among (i) Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), (ii) each of the Investors (as defined below) listed on Schedule A hereto, (iii) each person who hereafter becomes a party to this Agreement in accordance with Subsection 6.1 or Subsection 6.9 hereof, and (iv) solely with respect to Section 4 and Section 6, the Massachusetts Institute of Technology (“MIT”).
LEASE AGREEMENTLease Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT is made as of this 24th day of August, 2017, between ARE-MA REGION NO. 45, LLC, a Delaware limited liability company (“Landlord”), and FOGHORN THERAPEUTICS INC., a Delaware corporation (“Tenant”).
SEVERANCE WAIVER AND LETTER AGREEMENT AMENDMENTSeverance Waiver and Letter Agreement Amendment • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Sigilon Therapeutics, Inc. (the “Company”) and (the “Executive”) entered into a letter agreement dated for the purpose of establishing the terms and conditions of Executive’s employment (the “Letter Agreement”);
SEVERANCE WAIVER AND OFFER LETTER AMENDMENTSeverance Waiver and Offer Letter Amendment • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Sigilon Therapeutics, Inc. (the “Company”) and Rogerio Vivaldi Coelho (the “Executive”) entered into a letter agreement dated April 23, 2018 for the purpose of establishing the terms and conditions of Executive’s employment (the “Letter Agreement”);
Wednesday, May 8, 2019 Glenn Reicin glenn@grevrockbiomed.com Dear Glenn,Employment Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Sigilon Therapeutics (the “Company”), a Flagship Pioneering Company, I am delighted to make this conditional offer of employment with the Company. This offer letter (the “Offer Letter”) and the accompanying documents and agreements summarize and set forth important terms about your employment with the Company.
ASSIGNMENT AND ASSUMPTION OF LEASEAssignment and Assumption of Lease • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This ASSIGNMENT AND ASSUMPTION OF LEASE (this “Assignment”), dated as of October 21, 2019, is made and entered into by and among FOGHORN THERAPEUTICS INC., a Delaware corporation (“Assignor”) and SIGILON THERAPEUTICS, INC., a Delaware corporation (“Assignee”).
CONSENT TO ASSIGNMENT AND FIRST AMENDMENT TO LEASELease Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This Consent to Assignment and First Amendment to Lease (this “Consent”) is made as of October 21, 2019, between and among ARE-MA REGION NO. 45, LLC, a Delaware limited liability company (“Landlord”), FOGHORN THERAPEUTICS INC., a Delaware corporation (“Tenant”), and SIGILON THERAPEUTICS, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.
